Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. (Q38033044)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 August 2012

Language	Label	Description	Also known as
English	Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.	scientific article published on 10 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mary Angelyn Bethel

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Benjamin Cairns

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Francesca L Crowe

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

R J Stevens

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Ali

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

C R Bankhead

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R P Camisasca

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A J Farmer

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Harrison

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

P Home

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Perera

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Plüddemann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Ramachandran

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

N W Roberts

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

P W Rose

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Schweizer

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Viberti

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

10 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

55

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

2593-2603

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

https://scigraph.springernature.com/pub.10.1007/s00125-012-2653-7

0 references

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Cohort study of pioglitazone and cancer incidence in patients with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Prevention of pancreatic cancer induction in hamsters by metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Metformin, diet and breast cancer: an avenue for chemoprevention.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2653-7

21 January 2018

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Metformin slows down ageing processes at the cellular level in SHR mice].

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin and risk of cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-012-2653-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875195%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38033044&oldid=1766079392"